162 related articles for article (PubMed ID: 25003667)
1. The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.
Exner R; Bago-Horvath Z; Bartsch R; Mittlboeck M; Retèl VP; Fitzal F; Rudas M; Singer C; Pfeiler G; Gnant M; Jakesz R; Dubsky P
Br J Cancer; 2014 Aug; 111(5):837-42. PubMed ID: 25003667
[TBL] [Abstract][Full Text] [Related]
2. Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study.
Wuerstlein R; Kates R; Gluz O; Grischke EM; Schem C; Thill M; Hasmueller S; Köhler A; Otremba B; Griesinger F; Schindlbeck C; Trojan A; Otto F; Knauer M; Pusch R; Harbeck N;
Breast Cancer Res Treat; 2019 Jun; 175(2):389-399. PubMed ID: 30796651
[TBL] [Abstract][Full Text] [Related]
3. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2- early breast cancer.
Slembrouck L; Vanden Bempt I; Wildiers H; Smeets A; Van Rompuy AS; Van Ongeval C; Jongen L; Weltens C; Punie K; Hoste G; Van Nieuwenhuysen E; Han S; Nevelsteen I; Neven P; Floris G
Mod Pathol; 2021 Jul; 34(7):1297-1309. PubMed ID: 33558657
[TBL] [Abstract][Full Text] [Related]
4. Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients with early stage breast cancer.
Gevensleben H; Göhring UJ; Büttner R; Heukamp LC; Kunz G; Dimpfl T; Jackisch C; Ortmann O; Albert US; Bender R; De Snoo F; Krijgsman O; Glas AM; Ergönenc YH; Vogel C; Dykgers A; Langwieder C; Rees M; Anzeneder T
Int J Mol Med; 2010 Dec; 26(6):837-43. PubMed ID: 21042777
[TBL] [Abstract][Full Text] [Related]
5. Genomic profiling of breast cancer in African-American women using MammaPrint.
Nunes RA; Wray L; Mete M; Herbolsheimer P; Smith KL; Bijelic L; Boisvert ME; Swain SM
Breast Cancer Res Treat; 2016 Oct; 159(3):481-8. PubMed ID: 27568021
[TBL] [Abstract][Full Text] [Related]
6. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
[TBL] [Abstract][Full Text] [Related]
7. Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases.
Sechrist H; Glasgow A; Bomeisl P; Gilmore H; Harbhajanka A
Hum Pathol; 2020 Oct; 104():54-65. PubMed ID: 32758491
[TBL] [Abstract][Full Text] [Related]
8. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
9. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis.
Harnan S; Tappenden P; Cooper K; Stevens J; Bessey A; Rafia R; Ward S; Wong R; Stein RC; Brown J
Health Technol Assess; 2019 Jun; 23(30):1-328. PubMed ID: 31264581
[TBL] [Abstract][Full Text] [Related]
10. The multigene classifiers 95GC/42GC/155GC for precision medicine in ER-positive HER2-negative early breast cancer.
Naoi Y; Tsunashima R; Shimazu K; Noguchi S
Cancer Sci; 2021 Apr; 112(4):1369-1375. PubMed ID: 33544932
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
[TBL] [Abstract][Full Text] [Related]
12. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
13. MammaPrint and BluePrint comprehensively capture the cancer hallmarks in early-stage breast cancer patients.
Haan JC; Bhaskaran R; Ellappalayam A; Bijl Y; Griffioen CJ; Lujinovic E; Audeh WM; Penault-Llorca F; Mittempergher L; Glas AM
Genes Chromosomes Cancer; 2022 Mar; 61(3):148-160. PubMed ID: 34841595
[TBL] [Abstract][Full Text] [Related]
14. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Kim MH; Kim GM; Kim JH; Kim JY; Park HS; Park S; Cho YU; Park BW; Kim SI; Sohn J
Breast Cancer Res Treat; 2020 Feb; 179(3):687-697. PubMed ID: 31811505
[TBL] [Abstract][Full Text] [Related]
15. Potential impact of the 70-gene signature in the choice of adjuvant systemic treatment for ER positive, HER2 negative tumors: a single institution experience.
Torrisi R; Garcia-Etienne CA; Losurdo A; Morenghi E; Di Tommaso L; Gatzemeier W; Sagona A; Fernandes B; Rossetti C; Eboli M; Rubino A; Barbieri E; Andreoli C; Orefice S; Gandini C; Rota S; Zuradelli M; Masci G; Santoro A; Tinterri C
Breast; 2013 Aug; 22(4):419-24. PubMed ID: 23643803
[TBL] [Abstract][Full Text] [Related]
16. An international study comparing conventional versus mRNA level testing (TargetPrint) for ER, PR, and HER2 status of breast cancer.
Wesseling J; Tinterri C; Sapino A; Zanconati F; Lutke-Holzik M; Nguyen B; Deck KB; Querzoli P; Perin T; Giardina C; Seitz G; Guinebretière JM; Barone J; Dekker L; de Snoo F; Stork-Sloots L; Roepman P; Watanabe T; Cusumano P
Virchows Arch; 2016 Sep; 469(3):297-304. PubMed ID: 27377889
[TBL] [Abstract][Full Text] [Related]
17. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.
Filipits M; Rudas M; Jakesz R; Dubsky P; Fitzal F; Singer CF; Dietze O; Greil R; Jelen A; Sevelda P; Freibauer C; Müller V; Jänicke F; Schmidt M; Kölbl H; Rody A; Kaufmann M; Schroth W; Brauch H; Schwab M; Fritz P; Weber KE; Feder IS; Hennig G; Kronenwett R; Gehrmann M; Gnant M;
Clin Cancer Res; 2011 Sep; 17(18):6012-20. PubMed ID: 21807638
[TBL] [Abstract][Full Text] [Related]
18. Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.
Chae EY; Moon WK; Kim HH; Kim WH; Cha JH; Shin HJ; Choi WJ; Han W; Noh DY; Lee SB; Ahn SH
PLoS One; 2016; 11(6):e0158461. PubMed ID: 27362843
[TBL] [Abstract][Full Text] [Related]
19. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
[TBL] [Abstract][Full Text] [Related]
20. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
Cai H; Guo W; Zhang S; Li N; Wang X; Liu H; Chen R; Wang S; Guo Z; Li J
Breast Cancer Res Treat; 2018 Jul; 170(2):271-277. PubMed ID: 29572677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
